Fondaparinux (Fund), a synthetic selective inhibitor of factor Xa, plays its role in controlling pulmonary embolism (PE) and deep vein thrombosis (DVT) and is often prescribed for post-operative patients of major abdominal, hip, or knee surgeries [27]. The gene discussed is F10; the disease is deep vein thrombosis.